Ventana platform

Manufactured by Roche

Sourced in United States

The Ventana platform is a fully automated, integrated system for the analysis of tissue samples in a clinical laboratory setting. It is designed to streamline the process of immunohistochemistry (IHC) and in situ hybridization (ISH) testing. The Ventana platform automates the staining and detection of specific proteins or genetic markers in tissue samples, providing standardized and consistent results.

Automatically generated - may contain errors

Lab products found in correlation

Pyromark q96 id system, by Qiagen (1 mentions) Aec kit, by Vector Laboratories (1 mentions) Ep888y, by Abcam (1 mentions) Ab179455, by Abcam (1 mentions)

Close spelling variants of this product

Ventana Benchmark Ultra platform (29 citations) Ventana Discovery Ultra platform (14 citations) Ventana BenchMark platform (10 citations) Ventana Benchmark XT platform (5 citations) Ventana Discovery XT platform (5 citations) Ventana Discovery XT Autostainer platform (4 citations) Ventana Discovery platform (3 citations) Ventana automated staining platform (3 citations) Ventana autostaining platform (2 citations) Ventana benchmark XT Automated Platform (2 citations)

12 protocols using ventana platform

Immunohistochemical Evaluation of DLL3

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumor tissue biopsied at any time prior to investigational imaging was assessed for DLL3 expression by IHC when feasible, using a standardized Ventana platform assay (clone SP347, Ventana, Roche, Tucson, AZ, USA)(22 (link)). Semi-quantitative assessment of DLL3 expression was based on estimating the percentage of positive tumor cells (tumor proportion score, range 0–100%) multiplied by staining intensity (range 0–3) to generate an H-score (range, 0–300).(23 (link)) All staining assessments were performed by a professional pathologist.

Tendler S., Dunphy M.P., Agee M., O’Donoghue J., Aly R.G., Choudhury N.J., Kesner A., Kirov A., Mauguen A., Baine M.K., Schoder H., Weber W.A., Rekhtman N., Lyashchenko S.K., Bodei L., Morris M.J., Lewis J.S., Rudin C.M, & Poirier J.T. (2024). First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate. medRxiv.

+ Open protocol

+ Expand

Molecular Profiling of Colorectal Cancers

Check if the same lab product or an alternative is used in the 5 most similar protocols

All the molecular analyses were performed according to the local clinical practice of the participating centers. KRAS, NRAS and BRAF mutational status was assessed with Sanger sequencing, real-time PCR techniques and next-generation sequencing (NGS) (such as: OncoGenBasic-S1 kit, Seqplexing (Valencia, Spain); Pyromark Q96 ID System, Qiagen (Hilden, Germany); EasyPGX and Myriapod Colon Status, Diatech Pharmacogenetics (Jesi, Italy)). MSI (microsatellite instability) status and/or MMR (mismatch repair) proteins expression were assessed with molecular sequencing (Sanger, Real-Time PCR and NGS) and Immunohistochemistry (IHC) (such as: Applied Biosystem 3500 DX genetic analyzer, Thermo Fisher Scientific (Waltham, MA, USA); Ultraview Universal Detection Kit and Ventana platform, Roche Tissue Diagnostics and Ventana Medical Systems (Tucson, AZ, USA)).

Parisi A., Cortellini A., Cannita K., Venditti O., Camarda F., Calegari M.A., Salvatore L., Tortora G., Rossini D., Germani M.M., Boccaccino A., Dell’Aquila E., Fulgenzi C., Santini D., De Tursi M., Tinari N., Di Marino P., Lombardi P., Roselló Keränen S., Huerta Álvaro M., Zurlo I.V., Corsi D.C., Emiliani A., Zanaletti N., Troiani T., Vitale P., Giampieri R., Merloni F., Occhipinti M.A., Marchetti P., Roberto M., Mazzuca F., Ghidini M., Indini A., Garajova I., Zoratto F., Delle Monache S., Porzio G, & Ficorella C. (2020). Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study. Cancers, 12(5), 1259.

+ Open protocol

+ Expand

Validating Osteosarcoma Biomarkers via IHC

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC experiment was performed using local hospital Biobank tissues to validate the differential expression of certain key gene in osteosarcoma comparing to adjacent normal tissues using local hospital Pathology Department instrument and equipment. The experiment was performed on VENTANA platform (Roche), the primary antibody of STC2 gene was purchased from proteintech (Cat No.60063-1-IG), the secondary antibody (Envision /HRP kit) and DAB detection kit were purchased from ZSBG-Bio by Immunohistochemistry Laboratory of Pathology Department, and other reagents including H2O2, phosphate-buffered saline (PBS), EDTA antigen retrieval citrate solution (PH = 8.8) and hematoxylin stain were all from hospital Supply Department.

Wang Z., Zeng Z., Gao F., Gui Z., Du J., Shen N., Shang Y., Yang Z., Shang L., Wei R., Ma W, & Wang C. (2023). Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression. BMC Medical Genomics, 16, 30.

+ Open protocol

+ Expand

Immunohistochemical Validation of GPRC5A and IMUP in Pancreatic Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC experiment was conducted using PAAD tissue microarray to validate the different expression of selected key genes in cancer comparing to normal pancreatic tissues. The experiment was performed on VENTANA platform (Roche) using local hospital Pathology Department equipment and regents. The primary antibody of key genes: anti-GPRC5A and anti-IMUP were both purchased from abcam (NO.ab155557 and ab221063 respectively). The secondary antibody (Envision /HRP kit) and DAB detection kit were from ZSBG-Bio purchased by Pathology Department, and other reagents including H2O2, phosphate-buffered saline (PBS), antigen retrieval citrate solution and hematoxylin stain were all from hospital Supply Department.

Wei R., Qi G., Zeng Z., Shen N., Wang Z., Shen H., Gao L., Song C., Ma W, & Wang C. (2021). IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma. Cancer Cell International, 21, 620.

+ Open protocol

+ Expand

Immunohistochemical Analysis of HER2/neu

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC for HER2/neu protein was performed on 2-3-micron thick paraffin embedded tissue sections placed on poly-L-lysine coated slides. Following deparaffinization and blocking of endogenous peroxidase, HER2/neu was done by applying c-erbB2 oncoprotein as primary antibody (Roche) on Ventana platform automated IHC stainer. Diaminobenzidine (DAB) was added as chromogen. Each slide was reviewed by a pathologist and immunostaining was read in semi quantitative manner according to ASCO/CAP recommended guidelines. IHC scores 0 and 1+ were designated as negative expression and 3+ were designated as positive expression. Score 2+, the grey zone area, was taken as equivocal and these slides were reviewed by two different pathologists who if reaffirmed the score of 2+ was further subjected to FISH testing.

Mukhtar Z., Faisal A., Mudassir G, & Mamoon N. (2023). Correlation between HER2/neu protein overexpression on Immunohistochemistry and Fluorescent in Situ Hybridization (FISH) in breast carcinoma: Problems in developing countries. Pakistan Journal of Medical Sciences, 39(6), 1814-1817.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Tissue Microarrays

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissue microarrays (TMAs) were constructed by using duplicate 0.6-mm cores from diagnostic (Arthur et al., 2018 (link)) and analyzed by immunohistochemistry using standard protocols (Dominguez-Sola and Cattoretti, 2017 (link)). Briefly, heat-induced epitope retrieval was performed in EDTA buffer (pH9.0) for phospho-AKT S473 or Citrate buffer (pH6.0) for FOXO1, followed by blocking endogenous peroxidase activity in PBS plus 3% H2O2. Phospho-AKT S473 staining was performed manually using a rabbit monoclonal anti-pAKT S473 antibody (Dako #M3628), by overnight incubation at 4^oC. After several washes, slides were incubated with an anti-Rabbit-HRP polymer secondary antibody (Rabbit Envision, Dako, Denmark) and developed using amino-ethyl-carbazole (AEC) as substrate (AEC kit, Vector Labs). FOXO1 staining was performed on the Ventana platform (Roche, Basel, Switzerland) using routine staining protocols (Arthur et al., 2018 (link)). All slides stained for both markers were reviewed and scored by an expert hematopathologist (P.F.).

Roberto M.P., Varano G., Vinas-Castells R., Holmes A.B., Kumar R., Pasqualucci L., Farinha P., Scott D.W, & Dominguez-Sola D. (2021). Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Immunity, 54(8), 1807-1824.e14.

+ Open protocol

+ Expand

Quantitative Immunohistochemical Analysis of Cyclin E1

Check if the same lab product or an alternative is used in the 5 most similar protocols

Sections from all FFPE blocks were simultaneously stained with anti-Cyclin E1 mouse monoclonal antibody (ab9517, Abcam, Burlingame, CA, USA) at 1:10 dilution for 1h at 37°C on a Ventana platform (Roche, Tucson, AZ, USA). Matching hematoxylin eosin (H & E)-stained sections were available for all CCNE1-stained sections, to confirm the correct identification of viable tumor cells. Staining intensity (ranging from 0 to 3) of immuno-positive tumor cells was evaluated by a certified pathologist applying routine rules of clinical histopathological examination. For each section the entire tissue area was examined and the percentage of cells at each category was determined. The total percentage of positive cells (PC) was calculated. In addition, an H-score, representing a weighted average of staining intensities (ranging from 0 to 300) was defined for each sample.

Sapoznik S., Aviel-Ronen S., Bahar-Shany K., Zadok O, & Levanon K. (2017). CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance. Oncotarget, 8(37), 62240-62247.

+ Open protocol

+ Expand

Immunohistochemistry of Clinical Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

All of the clinical patients sample were stored in our biobank, and they were all collected from routine surgeries at General Surgery Department and sent for pathology examination at the Department of Pathology of local Hospital. Informed consent from the patients as well as approval by the Hospital Institutional Board were obtained (ShanXi, China).
IHC experiment was performed on VENTANA platform (Roche), the TOP2A recombinant primary rabbit monoclonal antibody (SY27-00) was purchased from Invitrogen, secondary antibody (Envision/HRP kit) and DAB detection kit were from ZSBG-Bio. Other reagents including H₂O₂, phosphate-buffered saline (PBS) and hematoxylin stain were from the hospital supply department.

Ma W., Wang B., Zhang Y., Wang Z., Niu D., Chen S., Zhang Z., Shen N., Han W., Zhang X., Wei R, & Wang C. (2019). Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis. Cancer Cell International, 19, 239.

+ Open protocol

+ Expand

Tissue Microarrays for Protein Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tissue microarrays (TMAs) were constructed by using duplicate 0.6-mm cores from diagnostic pre-treatment FFPE tissue^{56 (link),57 (link)}. Staining was performed on the Ventana platform (Roche, Basel, Switzerland) using routine staining protocols. IHC staining for expression of CD32B (Abcam EP888Y) was independently reviewed by two hematopathologists (G.W.S. and P.F.).

Arthur S.E., Jiang A., Grande B.M., Alcaide M., Cojocaru R., Rushton C.K., Mottok A., Hilton L.K., Lat P.K., Zhao E.Y., Culibrk L., Ennishi D., Jessa S., Chong L., Thomas N., Pararajalingam P., Meissner B., Boyle M., Davidson J., Bushell K.R., Lai D., Farinha P., Slack G.W., Morin G.B., Shah S., Sen D., Jones S.J., Mungall A.J., Gascoyne R.D., Audas T.E., Unrau P., Marra M.A., Connors J.M., Steidl C., Scott D.W, & Morin R.D. (2018). Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nature Communications, 9, 4001.

+ Open protocol

+ Expand

Immunohistochemical Validation of FGF1 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC experiment was conducted using the ccRCC tissues microarray to validate the gene’s expression difference between cancer and paracancerous normal renal tissues. And it was performed on VENTANA platform (Roche) in local hospital Pathology Department. The primary antibody of FGF1 gene was purchased from abcam (ab179455), and the secondary antibody (Envision /HRP kit) and DAB detection kit were from ZSBG-Bio. Other reagents including H2O2, antigen retrieval citrate solution, phosphate-buffered saline (PBS) and hematoxylin stain were from local hospital Supply Department.

Zhang X., Wang Z., Zeng Z., Shen N., Wang B., Zhang Y., Shen H., Lu W., Wei R., Ma W, & Wang C. (2021). Bioinformatic analysis identifying FGF1 gene as a new prognostic indicator in clear cell Renal Cell Carcinoma. Cancer Cell International, 21, 222.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!